Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

Recruiting

Phase 1

BBI-940 & FulvestrantStudy of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

Sponsor:

Boundless Bio, Inc.

Code:

NCT07408089

Conditions

Breast Cancer

Metastatic Breast Cancer

Advanced Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BBI-940

Fulvestrant

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-05. This information was provided to ClinicalTrials.gov by Boundless Bio, Inc. on 2026-02-24.